| Rheumatoid Arthritis
Abrilada vs Otrexup
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Abrilada vs Otrexup with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOtrexup has a higher rate of injection site reactions vs Abrilada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Otrexup but not Abrilada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abrilada
Otrexup
At A Glance
SC injection
Every 1-2 weeks
TNF-alpha blocker
SC injection
Once weekly
Folate analog metabolic inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis Weight-based SC dosing every other week for patients 2 years of age and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction then 20 mg every other week (<40 kg) or 40 mg every other week (>=40 kg) starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Week 8 (Day 57).
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Rheumatoid Arthritis 7.5 mg SC once weekly; adjust dose gradually; doses greater than 20 mg/week associated with significant increase in serious toxic reactions in adults.
Juvenile polyarthritis 10 mg/m2 SC once weekly; adjust dose gradually.
Psoriasis 10 to 25 mg SC once weekly; do not exceed 30 mg/week; reduce to lowest effective dose once optimal response is achieved.
Contraindications
—
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, nausea, urinary tract infection, sinusitis, hyperlipidemia, flu syndrome, abdominal pain, back pain, hypercholesterolemia, hypertension
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, malignancies, hepatitis B reactivation, demyelinating disorders, hematologic reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, systemic vasculitis, deep vein thrombosis
Most common (>=10%) Elevated liver function tests, nausea/vomiting, ulcerative stomatitis, leukopenia, abdominal distress
Serious Bone marrow suppression, hepatotoxicity, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, renal failure, pulmonary fibrosis
Postmarketing Toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylactoid reactions, reversible lymphoma, skin necrosis
Pharmacology
Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody TNF-alpha blocker that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammation and modulating TNF-induced biological responses including leukocyte migration.
Methotrexate inhibits dihydrofolic acid reductase, preventing reduction of dihydrofolates to tetrahydrofolates and thereby interfering with DNA synthesis, repair, and cellular replication; in RA the mechanism is unknown but may affect immune function, and in psoriasis it exploits the markedly increased rate of epithelial cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abrilada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Otrexup
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Abrilada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Otrexup
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abrilada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Otrexup
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abrilada.
No savings programs available for Otrexup.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbriladaView full Abrilada profile
OtrexupView full Otrexup profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.